However, it cannot be the only analysis realized to process this genotyping because of the risk of missing some EGFR mutations, either in samples with few tumor cells or rare EGFR mutations not detected by rapid genotyping, but for which we will soon know whether they do or do not predict the response to EGFR-TKIs, and because NGS allows the analysis of a large panel of genes whose alterations (mutations and copy gain) can also guide the treatment decisions of patients with lung cancer. This evidence concerns the gene EGFR and neoplasm.